294 related articles for article (PubMed ID: 27292967)
21. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
22. [Impact of HLA compatibility on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia].
ZHANG Y; CHEN YK; FAN ZP; XU D; JIANG QL; SUN J; LIU QF
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Mar; 31(3):438-42. PubMed ID: 21421478
[TBL] [Abstract][Full Text] [Related]
23. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission.
Han LJ; Wang Y; Fan ZP; Huang F; Zhou J; Fu YW; Qu H; Xuan L; Xu N; Ye JY; Bian ZL; Song YP; Huang XJ; Liu QF
Br J Haematol; 2017 Oct; 179(1):120-130. PubMed ID: 28737249
[TBL] [Abstract][Full Text] [Related]
24. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant.
Xu LP; Jin S; Wang SQ; Xia LH; Bai H; Gao SJ; Liu QF; Wang JM; Wang X; Jiang M; Zhang X; Wu DP; Huang XJ
J Hematol Oncol; 2017 Jan; 10(1):25. PubMed ID: 28107815
[TBL] [Abstract][Full Text] [Related]
25. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
26. Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission.
Liu Y; Huang X; Fei Q; Xu L; Zhang X; Liu K; Chen Y; Chen H; Wang Y
Sci China Life Sci; 2019 May; 62(5):691-697. PubMed ID: 30194676
[TBL] [Abstract][Full Text] [Related]
27. Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study.
Wang Y; Liu QF; Xu LP; Liu KY; Zhang XH; Ma X; Wu MQ; Wu DP; Huang XJ
Clin Cancer Res; 2016 Jul; 22(14):3467-76. PubMed ID: 26927664
[TBL] [Abstract][Full Text] [Related]
28. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
29. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
30. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings.
Ma YR; Xu LP; Zhang XH; Liu KY; Chang YJ; Lv M; Yan CH; Chen YH; Han W; Wang FR; Mo XD; Huang XJ; Wang Y
Ann Hematol; 2021 Feb; 100(2):555-562. PubMed ID: 33415424
[TBL] [Abstract][Full Text] [Related]
32. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
[TBL] [Abstract][Full Text] [Related]
33. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
34. Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation.
Ma YR; Xu LP; Zhang XH; Yan CH; Wang Y; Wang FR; Wang JZ; Chen Y; Han W; Chen YH; Chen H; Liu KY; Huang XJ
Bone Marrow Transplant; 2017 Mar; 52(3):409-414. PubMed ID: 27797365
[TBL] [Abstract][Full Text] [Related]
35. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.
De Souza CA; Vigorito AC; Ruiz MA; Nucci M; Dulley FL; Funcke V; Tabak D; Azevedo AM; Byington R; Macedo MC; Saboya R; Penteado Aranha FJ; Oliveira GB; Zulli R; Martins Miranda EC; Azevedo WM; Lodi FM; Voltarelli JC; Simões BP; Colturato V; De Souza MP; Silla L; Bittencourt H; Piron-Ruiz L; Maiolino A; Gratwohl A; Pasquini R
Haematologica; 2005 Feb; 90(2):232-7. PubMed ID: 15710577
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
[TBL] [Abstract][Full Text] [Related]
37. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
[TBL] [Abstract][Full Text] [Related]
38. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study.
Zheng FM; Zhang X; Li CF; Cheng YF; Gao L; He YL; Wang Y; Huang XJ
Cancer Commun (Lond); 2020 Mar; 40(2-3):93-104. PubMed ID: 32175698
[TBL] [Abstract][Full Text] [Related]
39. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
[TBL] [Abstract][Full Text] [Related]
40. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia.
Zhang R; Shi W; Wang HF; You Y; Zhong ZD; Li WM; Zhang C; Lu X; Wang YD; Zheng P; Fang J; Hong M; Wu QL; Xia LH
Bone Marrow Transplant; 2017 Sep; 52(9):1253-1260. PubMed ID: 28581464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
